GENB (Generate Biomedicines) Total Liabilities: $953.38 Mil (As of Dec. 2025)


GENB Generate Biomedicines Inc GENB
6 GF Score
Price $16.92
! 2 Warning Signs
View Full Analysis

What is Generate Biomedicines Total Liabilities?

Generate Biomedicines GENB +2.18% 6 Total Liabilities is $953.38 Mil as of Dec. 2025. GuruFocus rates GENB with a GF Score™ of 6/100. The stock has 2 warning signs investors should review.

Generate Biomedicines's Total Liabilities for the quarter that ended in Dec. 2025 was $953.38 Mil.

Generate Biomedicines's quarterly Total Liabilities increased from . 20 ($0.00 Mil) to Dec. 2024 ($953.35 Mil) and increased from Dec. 2024 ($953.35 Mil) to Dec. 2025 ($953.38 Mil).

Generate Biomedicines's annual Total Liabilities increased from . 20 ($0.00 Mil) to Dec. 2024 ($953.35 Mil) and increased from Dec. 2024 ($953.35 Mil) to Dec. 2025 ($953.38 Mil).

Generate Biomedicines Total Liabilities Historical Data

* Premium members only.

The historical data trend for Generate Biomedicines's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Generate Biomedicines Total Liabilities Chart

Generate Biomedicines Annual Data
Trend Dec24 Dec25
Total Liabilities
953.35 953.38

Generate Biomedicines Semi-Annual Data
Dec24 Dec25
Total Liabilities 953.35 953.38
GENB
6GF Score
Generate Biomedicines Inc GENB
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Generate Biomedicines Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Generate Biomedicines's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=82.203+(53.518+813.147
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+4.511+0+0)
=953.38

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=330.182--623.197
=953.38

Generate Biomedicines's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=82.203+(53.518+813.147
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+4.511+0+0)
=953.38

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=330.182--623.197
=953.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $953.38 Mil mean?
Generate Biomedicines (GENB) has a Total Liabilities of $953.38 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Generate Biomedicines and its competitors.
Is Generate Biomedicines' Total Liabilities too high?
Generate Biomedicines' current Total Liabilities is $953.38 Mil. Overall, Generate Biomedicines has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Generate Biomedicines' Total Liabilities compare to PVLA and SLBT?
Generate Biomedicines' Total Liabilities of $953.38 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Generate Biomedicines and its competitors. Generate Biomedicines's current Total Liabilities is $953.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Generate Biomedicines stock overvalued right now?
Generate Biomedicines (GENB) has a current Total Liabilities of $953.38 Mil. The current Total Liabilities is $953.38 Mil. Generate Biomedicines' overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Generate Biomedicines (GENB), the current Total Liabilities is $953.38 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Generate Biomedicines Business Description

Address 101 South Street, Suite 900, Somerville, MA, USA, 02143
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
6GF Score

Get the complete analysis for GENB

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.92
Price